Asplenia screening: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Asplenia}} | {{Asplenia}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}}{{Anum Dilip}} | ||
==Overview== | ==Overview== | ||
| Line 32: | Line 32: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Primary care]] | |||
[[Category:Immunology]] | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Emergency medicine]] | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} | ||
Revision as of 02:42, 30 June 2020
|
Asplenia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Asplenia screening On the Web |
|
American Roentgen Ray Society Images of Asplenia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anum Dilip, M.B.B.S[2]
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]
References